Endothelial cells (EC) are sentinels of cardiovascular health. Their function is reduced by the presence of cardiovascular risk factors, and is regained once pathological stimuli are removed. In this European Society for Cardiology Position Paper we describe endothelial dysfunction as a spectrum of phenotypic states and advocate further studies to determine the role of EC subtypes in cardiovascular disease. We conclude that there is no single ideal method for measurement of endothelial function. Techniques to measure coronary epicardial and microvascular function are well established but they are invasive, time-consuming and expensive. Flow-mediated dilatation (FMD) of the brachial arteries provides a non-invasive alternative but is technically challenging and requires extensive training and standardization. We therefore propose that a consensus methodology for FMD is universally adopted to minimize technical variation between studies, and that reference FMD values are established for different populations of healthy individuals and patient groups. Newer techniques to measure endothelial function that are relatively easy to perform, such as finger plethysmography and the retinal flicker test, have the potential for increased clinical use provided a consensus is achieved on the measurement protocol used. We recommend further clinical studies to establish reference values for these techniques and to assess their ability to improve cardiovascular risk stratification. We advocate future studies to determine whether integration of endothelial function measurements with patient-specific epigenetic data and other biomarkers can enhance the stratification of patients for differential diagnosis, disease progression and responses to therapy.

Endothelial function in cardiovascular precision medicine : a position paper on behalf of the European Society of Cardiology / Y. Alexander, E. Osto, A. Schmidt-Trucksäss, M. Shechter, D. Trifunovic, D.J. Duncker, V. Aboyans, M. Bäck, L. Badimon, F. Cosentino, M. De Carlo, M. Dorobantu, D.G. Harrison, T.J. Guzik, I. Hoefer, P.D. Morris, G.D. Norata, R. Suades, S. Taddei, G. Vilahur, J. Waltenberger, C. Weber, F. Wilkinson, M. Bochaton-Piallat, P.C. Evans. - In: CARDIOVASCULAR RESEARCH. - ISSN 0008-6363. - 117:1(2021), pp. 29-42. [10.1093/cvr/cvaa085]

Endothelial function in cardiovascular precision medicine : a position paper on behalf of the European Society of Cardiology

G.D. Norata;
2021

Abstract

Endothelial cells (EC) are sentinels of cardiovascular health. Their function is reduced by the presence of cardiovascular risk factors, and is regained once pathological stimuli are removed. In this European Society for Cardiology Position Paper we describe endothelial dysfunction as a spectrum of phenotypic states and advocate further studies to determine the role of EC subtypes in cardiovascular disease. We conclude that there is no single ideal method for measurement of endothelial function. Techniques to measure coronary epicardial and microvascular function are well established but they are invasive, time-consuming and expensive. Flow-mediated dilatation (FMD) of the brachial arteries provides a non-invasive alternative but is technically challenging and requires extensive training and standardization. We therefore propose that a consensus methodology for FMD is universally adopted to minimize technical variation between studies, and that reference FMD values are established for different populations of healthy individuals and patient groups. Newer techniques to measure endothelial function that are relatively easy to perform, such as finger plethysmography and the retinal flicker test, have the potential for increased clinical use provided a consensus is achieved on the measurement protocol used. We recommend further clinical studies to establish reference values for these techniques and to assess their ability to improve cardiovascular risk stratification. We advocate future studies to determine whether integration of endothelial function measurements with patient-specific epigenetic data and other biomarkers can enhance the stratification of patients for differential diagnosis, disease progression and responses to therapy.
Endothelial function; Cardiovascular
Settore BIO/14 - Farmacologia
2021
13-apr-2020
Article (author)
File in questo prodotto:
File Dimensione Formato  
cvaa085.pdf

Open Access dal 14/04/2021

Tipologia: Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione 1.27 MB
Formato Adobe PDF
1.27 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/754676
Citazioni
  • ???jsp.display-item.citation.pmc??? 100
  • Scopus 156
  • ???jsp.display-item.citation.isi??? 145
social impact